Asset Details
Do you wish to reserve the book?
3PC-032 Autologous tissue adhesive in ophthalmological surgery
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
3PC-032 Autologous tissue adhesive in ophthalmological surgery
Do you wish to request the book?
3PC-032 Autologous tissue adhesive in ophthalmological surgery
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
3PC-032 Autologous tissue adhesive in ophthalmological surgery
2020
Overview
Background and importanceSutures to replace tissue adhesives have enhanced importance. However, commercialised drugs are allogenic, synthetic and expensive, increasing surgery costs.Aim and objectivesTo produce an autologous tissue adhesive (ATA) easily compounded in ophthalmological surgery.To show evidences of the safe and effectiveness of the ATA in preclinical studies.Material and methodsTo produce 4 mL of ATA based on a fibrinogen (FC) and thrombin concentrate (TC) (proportion1:1), 20 mL of donor blood plasma were precipitated with protamine to prepare FC, and then 20 mL of plasma were precipitated with acetic acid to obtain a TC in a buffer (CaCl2, NaHCO3, NaCl). Drug was conditioned in two 2 mL syringes for topical ophthalmic administration by mixing with a needle.The in vitro toxicity of the drug was studied in a human corneal epithelial model (described as QobuR), to evaluate the grade of irritation after 30 min of exposition time.1Pterygium surgery was performed in four eyes of white New Zealand rabbits, using ATA to fix a frontal conjunctival autograft (4×5 mm) into the temporal bulbar conjunctive.The grafted eyes were evaluated in vivo by clinical evaluation for 14–28 days and ex vivo by histology.ResultsATA produced from each donor showed a mean of 18.0 g/L of fibrinogen and 1500 UI/mL of thrombin. ATA instantly produced homogeneous clots when it was mixed with a needle.Three in vitro studies of four ATA showed non-irritation due to high survival cell viabilities (>80%).Good preclinical results were found:20 mm2 autograft could be fixed successfully.Time for complete tissue adhesion was minimal (3–5 min).Inflammation and adverse events were absent in all cases.The prospective clinical evaluation was positive for follow-up in all cases and included integration and vascularisation of the grafts.Histology supported the in vivo evidence. Staining of the autograft section showed inner vessels and the regeneration of the surrounding conjunctive tissue.Conclusion and relevanceIt is possible to compound an ATA easily from whole blood, in a hospital pharmacy, for ophthalmological surgery, where the necessary volume is very low. This ATA was safe and effective, supported by our preclinical studies. This ATA could allow the possibility of replacing the suture in surgery with a low cost drug.References and/or acknowledgements1. https://www.ncbi.nlm.nih.gov/pubmed/30690064No conflict of interest.
